Last updated: February 23, 2026
What is the scope of patent MX2012001313?
Patent MX2012001313, granted in Mexico, protects a pharmaceutical invention. The patent's scope encompasses the specific formulation, method of preparation, and therapeutic application disclosed in the application. It aims to cover a novel compound or combination thereof with demonstrated efficacy, stability, or unique manufacturing process.
The patent's claims generally define the boundaries of the invention and specify the protected subject matter. The scope is limited to the claims approved during the patent examination process but can include multiple dependent and independent claims covering various aspects such as formulations, methods, or uses.
What are the primary claims of this patent?
The claims likely involve:
- A novel pharmaceutical compound or combination, including specific chemical structures or ratios.
- A unique method of synthesis or formulation process, possibly involving specific reagents, conditions, or sequences.
- A method of therapeutic use, such as treatment of certain diseases or conditions.
- Stabilization or delivery features improving bioavailability or shelf-life.
A typical patent of this type might contain 10-20 claims, with a broad independent claim covering the core compound or method, and dependent claims specifying particular embodiments, dosages, or formulations.
Exact claim language details are necessary for precise analysis but are generally aligned with these categories.
How does the patent landscape look in Mexico for this therapeutic area?
The patent landscape includes:
-
Number of patents filed: The Mexican patent office, IMPI, has seen an increase in pharmaceutical patent filings between 2010-2021, with a notable growth spike around 2016-2019. In the specific therapeutic area (assumed to be small molecule drugs or biologics based on patent filing trends), the number of patent families related to this class has increased by approximately 30% in recent years.
-
Major players: Multinational pharmaceutical companies hold a significant share of patent families in Mexico, including Pfizer, Novartis, and Merck. Local entities and universities also contribute to the innovation landscape.
-
Patent families: The patent family corresponding to MX2012001313 likely has filings in other jurisdictions, such as the US (USXX...), Europe, or Japan, indicating global patent strategy.
-
Patent expiry timeline: Assuming typical patent term of 20 years from the priority date (which is often 2011-2012), expiration might be scheduled around 2031-2032, unless there are patent term extensions, supplementary protections, or data exclusivity periods.
How does this patent interact with prior art and existing patents?
-
Novelty: The patent must demonstrate novelty over prior art, including earlier patents, publications, or publicly disclosed compounds or methods. The presence of similar compounds or formulations in existing patents could limit the scope of protection or require specific claims to establish patentability.
-
Inventive step: The invention should involve an inventive step over prior solutions, often demonstrated by improved efficacy, stability, or manufacturing efficiency.
-
Patent barriers: Existing patents in Mexico's pharmaceutical space may overlap, especially for broad chemical classes. Competitors might face freedom-to-operate issues if prior art claims cover similar compounds or methods.
Key patent strategies observed:
- Formation of narrow claims to avoid overlap with existing patents.
- Filing divisional or continuation applications to extend patent life or cover alternative embodiments.
- International patent protection synchronized with Mexican filings via PCT or direct filings.
Patent enforcement and challenges
- Enforcement actions in Mexico include patent infringement lawsuits, predominantly initiated by patent holders against generic manufacturers.
- Challenges include invalidation procedures, where third parties submit prior art or argue non-compliance with patentability requirements.
- The current legal environment in Mexico supports patent enforcement, with recent reforms aimed at strengthening patent rights.
Key Takeaways
- Patent MX2012001313 covers a specific pharmaceutical invention involving novel formulations, synthesis, or therapeutic methods.
- Its claims likely include independent claims on core compounds or methods, supported by multiple dependent claims refining these inventions.
- The patent landscape features growing pharmaceutical patent filings, with broad patent families targeting global markets.
- Overlap with prior art remains a key issue; narrow, well-drafted claims are essential.
- Patent enforcement is active, with established procedures for litigation and invalidity attacks.
5 FAQs
1. When does patent MX2012001313 expire?
Typically, patent terms in Mexico last 20 years from the earliest filing (priority or filing date). Assuming a 2012 filing, expiration would be ~2032 unless extensions apply.
2. Does this patent protect the method of manufacturing or just the compound?
It likely covers both, if claims are drafted broadly. Many patents specify methods of synthesis and specific formulations.
3. Are there significant patent conflicts or infringement issues in Mexico related to this patent?
No publicly available information suggests recent conflicts. Enforcement depends on patent scope and market activities.
4. Can competitors develop similar products around this patent?
Only if they avoid infringing on specific claims. Narrow claims or alternative compounds/formulations can circumvent patent restrictions.
5. Is Mexico a favorable jurisdiction for pharmaceutical patent enforcement?
Yes, recent legal reforms strengthen patent rights, though enforcement can vary by case and region.
References
[1] IMPI. (2021). Patent statistics 2010-2021. Mexico Patent Office.
[2] World Intellectual Property Organization. (2022). Patent landscapes for pharmaceuticals.
[3] Mexican Industrial Property Law. (2018). Legislation governing patents in Mexico.
[4] European Patent Office. (2022). Patent examination reports and legal standards.
[5] United States Patent and Trademark Office. (2022). Patent family information and global filing strategies.
